IDT Biologika, a Dessau, Germany-headquartered biopharmaceutical company, has established a new animal health organization in the Americas, IDT Animal Health Americas, which will offer a range of autogenous, wildlife, and commercial vaccines and diagnostic solutions for use in animals.

The company has appointed José Ochoa as head of IDT Animal Health Americas. Mr. Ochoa takes on the role within Animal Health while maintaining his position as chief business officer with IDT Biologika Corporation in Rockville, Maryland. Mr. Ochoa joined IDT from Emergent BioSolutions in 2015,

Jackie Gallant, founder and president of Gallant Custom Laboratories, sits on IDT’s scientific advisory board and will continue to oversee research and development of autogenous biologics, with a focus on animal health throughout Canada. Ms. Gallant will be supported by Dr. Guy Moser, general manager, Gallant Custom Laboratories, and Sam Mostafa, Gallant Custom Laboratories, who will serve as key account manager for animal health vaccines in Canada.

Andreas Kastenbauer, managing director of IDT, will continue to head IDT’s global animal health division.

In addition to establishing IDT Animal Health Americas, IDT concurrently launched its first fully licensed swine vaccine for Canada, Ecoporc SHIGA, developed by IDT. The vaccine reduces clinical symptoms, animal losses, and antibiotic use related to edema disease in swine. Further, as part of its strategy to build its global animal health vaccine network, IDT acquired Ridgeway Biologicals earlier in January. Ridgeway Biologicals is a Compton, UK-headquartered manufacturer of autogenous vaccines.

Source: IDT Biologika